Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Other Accumulated Expenses (2016 - 2025)

Historic Other Accumulated Expenses for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Q3 2025 value amounting to $2.7 million.

  • Rocket Pharmaceuticals' Other Accumulated Expenses fell 350.18% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 million, marking a year-over-year decrease of 350.18%. This contributed to the annual value of $1.6 million for FY2024, which is 829.57% down from last year.
  • Per Rocket Pharmaceuticals' latest filing, its Other Accumulated Expenses stood at $2.7 million for Q3 2025, which was down 350.18% from $1.7 million recorded in Q2 2025.
  • Rocket Pharmaceuticals' 5-year Other Accumulated Expenses high stood at $3.1 million for Q2 2024, and its period low was $482000.0 during Q4 2021.
  • For the 5-year period, Rocket Pharmaceuticals' Other Accumulated Expenses averaged around $1.7 million, with its median value being $1.7 million (2025).
  • Per our database at Business Quant, Rocket Pharmaceuticals' Other Accumulated Expenses skyrocketed by 37157.68% in 2022 and then crashed by 4416.86% in 2025.
  • Quarter analysis of 5 years shows Rocket Pharmaceuticals' Other Accumulated Expenses stood at $482000.0 in 2021, then soared by 371.58% to $2.3 million in 2022, then fell by 22.04% to $1.8 million in 2023, then fell by 8.3% to $1.6 million in 2024, then soared by 64.49% to $2.7 million in 2025.
  • Its last three reported values are $2.7 million in Q3 2025, $1.7 million for Q2 2025, and $2.9 million during Q1 2025.